Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,560 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines 2022.
Jiang Z, Li J, Chen J, Liu Y, Wang K, Nie J, Wang X, Hao C, Yin Y, Wang S, Yan M, Wang T, Yan Y, Chen X, Song E; CSCO BC guideline working group. Jiang Z, et al. Transl Breast Cancer Res. 2022 Apr 30;3:13. doi: 10.21037/tbcr-22-21. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751537 Free PMC article. Review.
Efficacy and safety of margetuximab plus chemotherapy vs. trastuzumab plus chemotherapy in Chinese patients with pretreated HER2-positive advanced metastatic breast cancer: results from a randomized, open-label, multicenter, phase II bridging study.
Zhang Q, Ouyang Q, Li W, Chiu J, Yan M, Lu YS, Sun S, Li H, Du Y, Wang X, Sun T, Yin Y, Wang H, Ye F, Shen K, Wang J, Pan Y, Wang S, Yang J, Wu X, Dai MS, Cheng J, Teng Y, Su F, Wu X, He J, Fu P, Yang L, Xin Y, Wang X, Jiang Z. Zhang Q, et al. Among authors: ouyang q. Transl Breast Cancer Res. 2022 Oct 31;3:31. doi: 10.21037/tbcr-22-35. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751523 Free PMC article.
CSCO expert consensus on the diagnosis and treatment of breast cancer brain metastasis.
Wang T, Chen J, Yang J, Fu M, Hua W, Jia W, Liu Y, Wang B, Yan M, Zhou J, Hao C, Chen J, Ou D, Jiang T, Mao Y, Jiang Z; CSCO expert panel of breast cancer*; CSCO expert panel of breast cancer. Wang T, et al. Transl Breast Cancer Res. 2022 Jul 30;3:22. doi: 10.21037/tbcr-22-30. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751521 Free PMC article. Review.
Efficacy and safety of abemaciclib-based therapy versus tucidinostat-based therapy after progression on palbociclib in patients with HR+HER2- metastatic breast cancer.
Yuan Y, Zhang S, Wang T, Wang B, Wang S, Shi J, Sun T, Yin Y, Ouyang Q, Li J, Wen Y, Zhang L, Jiang Z. Yuan Y, et al. Among authors: ouyang q. Transl Breast Cancer Res. 2023 Apr 30;4:10. doi: 10.21037/tbcr-23-9. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751483 Free PMC article.
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer: a long-term safety and overall survival update from the randomised, double-blind, placebo-controlled, phase 3 trial.
Zhang Q, Li W, Hu X, Sun T, Cui S, Wang S, Ouyang Q, Yin Y, Geng C, Tong Z, Cheng Y, Ning Z, Jiang Z. Zhang Q, et al. Among authors: ouyang q. Transl Breast Cancer Res. 2023 Jul 30;4:18. doi: 10.21037/tbcr-23-31. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751475 Free PMC article.
1,560 results